title: Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: A L
authors.identifier: 0000000327915748
authors.initials: AL
authors.lastname: Garfall
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Dougherty
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: D T
authors.initials: DT
authors.lastname: Vogl
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Weiss
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Cohen
authors.affiliation: Center for Clinical Epidemiology & Biostatistics, Department of Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Mick
authors.affiliation: Division of Transfusion Medicine, Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: U
authors.initials: U
authors.lastname: O'Doherty
authors.affiliation: Hematologic Malignancies Program, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D064592:Autografts; D001596:Benzylamines; D000080027:Cyclams; D018572:Disease-Free Survival; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality* / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D019380:Anti-HIV Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim; C088327:plerixafor